Analyst Rating Update on Emergent Biosolutions (EBS)

Emergent Biosolutions (NYSE:EBS) : Zacks Investment Research ranks Emergent Biosolutions (NYSE:EBS) as 4, which is a Sell recommendation. 3 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 1 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 4 research analysts is 1.5, which indicates as a Strong Buy.

Emergent Biosolutions (NYSE:EBS) stock is expected to deviate a maximum of $9.9 from the average target price of $40 for the short term period. 2 Street Experts have initiated coverage on the stock with the most promising target being $47 and the most muted being $33.

For the current week, the company shares have a recommendation consensus of Buy. Also, Chardan Capital initiates coverage on Emergent Biosolutions (NYSE:EBS) In a research note issued to the investors, the brokerage major announces price-target of $47 per share.The shares have been rated Buy. The rating by the firm was issued on April 15, 2016.

Emergent Biosolutions (NYSE:EBS): stock turned positive on Tuesday. Though the stock opened at $27.52, the bulls momentum made the stock top out at $28.34 level for the day. The stock recorded a low of $27.01 and closed the trading day at $28.32, in the green by 3.96%. The total traded volume for the day was 1,408,594. The stock had closed at $27.24 in the previous days trading.

In an insider trading activity, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director of Emergent Biosolutions Inc., Joulwan George A had sold 4,700 shares worth of $207,364 in a transaction dated June 6, 2016. In this transaction, 4,700 shares were sold at $44.12 per share.

Emergent BioSolutions Inc. is a biopharmaceutical company that offers specialized products to healthcare providers and Governments to address medical needs and emerging health threats. The Companys two operating divisions include Biodefense and Biosciences. The Companys Biodefense division is a pharmaceutical business focused on countermeasures that address CBRNE (Chemical, Biological, Radiological, Nuclear and Explosives) threats. The Biodefense divisions marketed products are BioThrax; BAT; Anthrasil; VIGIV, and RSDL. The Biodefense division investigational stage product candidates include NuThrax, PreviThrax, GC-072 and other biodefense product candidates. The Biosciences divisions marketed products are WinRho SDF, HepaGam B, VARIZIG and episil. The Biosciences division investigational stage product candidates include IXINITY, ES414 and otlertuzumab.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *